21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU

Key Takeaways Explain This Topic AI

The landmark Villanueva randomized trial established that a restrictive red blood cell transfusion strategy (transfusion threshold hemoglobin < 7 g/dL <7\text{ g/dL} < 7 g/dL with a target range of 7 − 8 g/dL 7-8\text{ g/dL} 7 − 8 g/dL ) significantly improves 6-week survival, lowers rebleeding rates, and minimizes adverse events compared to a liberal strategy ( < 9 g/dL <9\text{ g/dL} < 9 g/dL ), because excessive intravascular volume expansion escalates portal venous pressures and disrupts early hemostatic clots.

High-risk non-variceal peptic ulcers categorized by the Forrest classification (active spurting [Ia], active oozing [Ib], and non-bleeding visible vessels [IIa]) mandate definitive dual endoscopic therapy—combining dilute epinephrine injection for initial visualization with thermal contact electrocoagulation or through-the-scope / over-the-scope mechanical hemoclips—followed by high-dose intravenous proton pump inhibitor therapy for 72 hours.

Acute variceal upper gastrointestinal hemorrhage mandates immediate pre-endoscopic pharmacotherapy with continuous splanchnic vasoactive infusions (octreotide 50 μ g 50\ \mu\text{g} 50 μ g IV bolus followed by 50 μ g/h 50\ \mu\text{g/h} 50 μ g/h ) and antibiotic prophylaxis (ceftriaxone 1 g 1\text{ g} 1 g IV daily for 7 days), followed by urgent esophagogastroduodenoscopy (EGD) within 12 hours for endoscopic variceal ligation (EVL).

In refractory, exsanguinating variceal hemorrhage, balloon tamponade using a Sengstaken-Blakemore or Minnesota tube serves strictly as an emergency temporary bridge ( < 24 hours <24\text{ hours} < 24 hours ) to definitive intervention; it requires elective endotracheal intubation prior to tube placement, inflation of the gastric balloon with 250 − 300 mL 250-300\text{ mL} 250 − 300 mL of air, continuous traction, and urgent evaluation for early preemptive transjugular intrahepatic portosystemic shunt (TIPS).

For acute lower gastrointestinal bleeding (LGIB) presenting with hemodynamic instability or massive hematochezia, urgent multiphase computed tomography angiography (CTA) without oral contrast is the primary diagnostic imaging modality of choice (detecting active extravasation at rates ≥ 0.3 − 0.5 mL/min \ge 0.3-0.5\text{ mL/min} ≥ 0.3 − 0.5 mL/min ), guiding immediate transcatheter arterial embolization (TAE), whereas colonoscopy is reserved for stabilized patients following rapid oral polyethylene glycol purge.

Last updated: October 2026

Resuscitation Physiology and Restrictive Transfusion Strategy

Acute gastrointestinal bleeding (GIB) represents one of the most frequent causes of admission to the intensive care unit. Critical care management begins with rapid assessment of airway stability, intravascular volume resuscitation, and correction of physiological derangements before definitive diagnostic endoscopic localization.

The Villanueva Trial and Transfusion Physiology

Historically, clinicians resuscitated acute upper gastrointestinal bleeding (UGIB) with liberal blood transfusions targeting normal hemoglobin levels ( > 10 g/dL >10\text{ g/dL} > 10 g/dL ). However, the seminal multicenter randomized controlled trial by Villanueva et al. (NEJM 2013) transformed clinical practice by demonstrating the superiority of a restrictive transfusion strategy :

Restrictive Strategy : Packed red blood cells (PRBCs) transfused only when hemoglobin dropped below 7 g/dL 7\text{ g/dL} 7 g/dL , targeting a post-transfusion hemoglobin of 7 − 8 g/dL 7-8\text{ g/dL} 7 − 8 g/dL .

Liberal Strategy : PRBCs transfused when hemoglobin dropped below 9 g/dL 9\text{ g/dL} 9 g/dL , targeting a hemoglobin of 9 − 11 g/dL 9-11\text{ g/dL} 9 − 11 g/dL .

In this landmark trial of 921 patients, the restrictive transfusion strategy demonstrated a statistically significant reduction in all-cause 6-week mortality (5% vs. 9%, hazard ratio 0.55; P = 0.02 P = 0.02 P = 0.02 ), a marked decrease in recurrent bleeding (10% vs. 16%; P = 0.01 P = 0.01 P = 0.01 ), and significantly fewer overall adverse events (40% vs. 48%; P = 0.02 P = 0.02 P = 0.02 ). The survival benefit was most pronounced in patients with cirrhosis and Child-Pugh class A and B disease. [Acute Severe Gastrointestinal Hemorrhage]

│
Hemodynamic Assessment & Access
(2 large-bore peripheral IVs or Cordis)
│
┌───────────────┴───────────────┐
▼ ▼
Cirrhotic / Variceal Suspicion Non-Variceal Presentation
│ │
├─ Octreotide Bolus + Infusion ├─ High-Dose IV PPI (80 mg bolus)
├─ Ceftriaxone 1 g IV daily ├─ Restrictive PRBC (Trigger Hgb < 7)
├─ Restrictive PRBC (Hgb 7-8) └─ Urgent EGD within 24 Hours
├─ Urgent EGD within 12 Hours
└─ High Risk? Early TIPS (24-72h)

Important

Pathophysiological Basis for Restrictive Transfusion :

Liberal volume expansion and over-transfusion cause acute expansion of the splanchnic intravascular volume. In portal hypertension, this rapidly elevates the hepatic venous pressure gradient (HVPG), increasing wall tension across fragile esophageal and gastric varices. In both variceal and non-variceal bleeding, rapid cold fluid and blood administration produces dilutional coagulopathy, impairs platelet aggregation, and physically dislodges freshly formed, fragile hemostatic fibrin clots through increased capillary hydrostatic pressure.

Exceptions to Restrictive Strategy : A restrictive threshold ( < 7 g/dL <7\text{ g/dL} < 7 g/dL ) applies universally to stable and critically ill patients with acute UGIB, except those with ongoing acute myocardial ischemia, symptomatic coronary artery disease, or active refractory exsanguinating hemorrhagic shock, where a higher hemoglobin target of 8 − 9 g/dL 8-9\text{ g/dL} 8 − 9 g/dL is prudent.

Airway Protection and Pre-Endoscopic Pharmacotherapy

Patients presenting with ongoing massive hematemesis, depressed level of consciousness (Glasgow Coma Scale < 8 <8 < 8 ), or severe hepatic encephalopathy require elective endotracheal intubation prior to upper endoscopy to prevent catastrophic pulmonary aspiration of blood and gastric contents. Intubation should be performed using rapid sequence induction with hemodynamic optimization to prevent post-induction circulatory collapse.

Erythromycin Administration : Intravenous erythromycin ( 250 mg 250\text{ mg} 250 mg IV infused over 30 − 60 minutes 30-60\text{ minutes} 30 − 60 minutes , administered 30 − 90 minutes 30-90\text{ minutes} 30 − 90 minutes prior to EGD) acts as a motilin receptor agonist. It accelerates gastric emptying, clears blood, organized clots, and food residues from the gastric fundus and antrum, significantly improving mucosal visualization, shortening procedural duration, and reducing the requirement for a second-look endoscopy.

Non-Variceal Upper GI Bleeding: Peptic Ulcer Disease & Forrest Classification

Peptic ulcer disease (PUD)—encompassing duodenal and gastric ulcers—accounts for 50% to 60% of all acute non-variceal UGIB admissions. Arterial hemorrhage occurs when acid-peptic ulceration erodes deeply through the submucosa and muscularis propria into major underlying vessels, such as the gastroduodenal artery (posterior duodenal bulb ulcers) or the left gastric artery (lesser curvature gastric ulcers).

Forrest Classification and Risk Stratification

The Forrest classification categorizes bleeding peptic ulcers based on their endoscopic stigmata of recent hemorrhage, directly determining rebleeding risk and guiding the necessity for endoscopic hemostatic therapy:

Forrest Class Endoscopic Description Risk of Rebleeding Without Therapy Recommended Intervention

Class Ia Spurting arterial hemorrhage 80 − 90 % 80-90\% 80 − 90% Mandatory Dual Endoscopic Therapy + IV PPI Infusion

Class Ib Oozing hemorrhage without spurting 20 − 30 % 20-30\% 20 − 30% Mandatory Dual Endoscopic Therapy + IV PPI Infusion

Class IIa Non-bleeding visible vessel 40 − 50 % 40-50\% 40 − 50% Mandatory Dual Endoscopic Therapy + IV PPI Infusion

Class IIb Adherent clot over ulcer base 15 − 25 % 15-25\% 15 − 25% Targeted vigorous clot irrigation; if underlying visible vessel or active bleeding exposed, apply dual therapy; IV PPI

Class IIc Flat pigmented / hematin spot < 5 − 10 % <5-10\% < 5 − 10% No endoscopic therapy indicated ; oral PPI; can step down to ward

Class III Clean ulcer base < 2 − 5 % <2-5\% < 2 − 5% No endoscopic therapy indicated ; oral PPI; early discharge / rooming

Dual Endoscopic Therapy Paradigm

Guidelines strictly mandate that endoscopic injection of dilute epinephrine ( 1 : 10 , 000 1:10,000 1 : 10 , 000 or 1 : 20 , 000 1:20,000 1 : 20 , 000 ) must never be utilized as monotherapy . While local epinephrine injection produces transient interstitial tamponade and arteriolar vasoconstriction, it does not achieve definitive vessel thrombosis and yields unacceptably high rates of secondary rebleeding.

Epinephrine injection must always be paired with a second, definitive hemostatic modality:

Thermal Contact Devices : Bipolar electrocoagulation or heater probe thermocoagulation applies physical coaptive pressure to compress the vessel lumen, followed by thermal energy delivery to seal the arterial walls.

Mechanical Devices : Through-the-scope clips (TTSC) or over-the-scope clips (OTSC) physically grasp and appose the bleeding vessel and surrounding fibrotic submucosa, achieving immediate mechanical occlusion without inducing additional tissue necrosis. OTSC systems are particularly effective for large ( > 1.5 − 2 cm >1.5-2\text{ cm} > 1.5 − 2 cm ), fibrotic, chronic ulcers where conventional TTS clips fail.

Topical Hemostatic Agents : Hemostatic powders (e.g., TC-325) provide rapid temporary bridging in diffuse, friable oozing malignant lesions or massive bleeding where direct vessel localization is obscured.

Acid Suppression Physiology

Gastric acid profoundly inhibits hemostasis: at a pH < 6.0 \text{pH} < 6.0 pH < 6.0 , platelet aggregation is abolished, platelet disaggregation occurs, and pepsinogen is activated to pepsin, which actively lyses newly formed fibrin clots. Maintaining an intragastric pH ≥ 6.0 \text{pH} \ge 6.0 pH ≥ 6.0 stabilizes the hemostatic clot.

High-Dose Intravenous PPI Regimen : Intravenous omeprazole or pantoprazole administered as an 80 mg 80\text{ mg} 80 mg IV bolus , followed by a continuous infusion of 8 mg/h 8\text{ mg/h} 8 mg/h for 72 hours (the window during which > 80 % >80\% > 80% of ulcer rebleeding occurs).

Intermittent Dosing Non-Inferiority : Multiple meta-analyses have demonstrated that high-dose intermittent IV PPI (e.g., pantoprazole 40 − 80 mg 40-80\text{ mg} 40 − 80 mg IV twice daily) achieves equivalent 72-hour rebleeding rates, surgical interventions, and mortality compared to continuous infusion regimens.

Acute Variceal Hemorrhage Emergency Management Protocol

Esophageal and gastric varices develop as collateral circulations secondary to portal hypertension. The hepatic venous pressure gradient (HVPG) —the difference between the wedged hepatic venous pressure and the free hepatic venous pressure—reflects portal pressure. Normal HVPG is 1 − 5 mmHg 1-5\text{ mmHg} 1 − 5 mmHg . An HVPG ≥ 10 mmHg \text{HVPG} \ge 10\text{ mmHg} HVPG ≥ 10 mmHg defines clinically significant portal hypertension, and an HVPG ≥ 12 mmHg \text{HVPG} \ge 12\text{ mmHg} HVPG ≥ 12 mmHg represents the critical threshold required for variceal formation and rupture.

Pre-Endoscopic Medical Triad

When variceal hemorrhage is suspected in a patient with chronic liver disease, three medical interventions must be initiated immediately, well before endoscopic intervention: [Suspected Variceal Upper GI Bleeding]

│
Immediate Medical Stabilization
┌────────────────┼────────────────┐
▼ ▼ ▼
Splanchnic Antibiotic Restrictive
Vasoconstrictor Prophylaxis Transfusion
(Octreotide) (Ceftriaxone) (Hgb 7-8 g/dL)
1. Vasoactive Splanchnic Infusions

Vasoactive drugs reduce splanchnic arterial blood flow and decrease portal inflow, thereby rapidly lowering portal venous pressure and HVPG:

Octreotide : A synthetic somatostatin analogue. Initiated as an immediate intravenous bolus of 50 μ g 50\ \mu\text{g} 50 μ g IV , followed by a continuous infusion of 50 μ g/h 50\ \mu\text{g/h} 50 μ g/h , maintained for 2 to 5 days .

Terlipressin : A synthetic vasopressin analogue with selective V 1 V_1 V 1 vascular receptor agonism (bolus 2 mg 2\text{ mg} 2 mg IV every 4 hours, titrated down to 1 mg 1\text{ mg} 1 mg q4h). While standard in Europe and internationally, octreotide remains the primary agent in North American centers.

2. Antimicrobial Prophylaxis

Cirrhotic patients presenting with acute UGIB suffer profound reticuloendothelial dysfunction, bacterial translocation from gut congestion, and high rates of spontaneous bacterial peritonitis (SBP), pneumonia, and bacteremia. Systemic infections stimulate endothelial endothelin and nitric oxide imbalances, precipitating rebound portal pressure surges and rebleeding.

Ceftriaxone : Administered as 1 g 1\text{ g} 1 g IV every 24 hours for 7 days . Ceftriaxone significantly reduces bacterial infections, reduces the incidence of early recurrent bleeding, and provides a proven all-cause mortality benefit in cirrhotic patients with GI hemorrhage.

3. Restrictive PRBC Transfusion

Targeting hemoglobin between 7 7 7 and 8 g/dL 8\text{ g/dL} 8 g/dL avoids portal pressure spikes and secondary rupture.

Endoscopic Intervention

Urgent upper endoscopy should be performed as soon as resuscitation is established, ideally within 12 hours of presentation :

Esophageal Varices : Endoscopic Variceal Ligation (EVL) is the definitive first-line endoscopic treatment. Elastic rubber bands are deployed over the variceal columns starting at the gastroesophageal junction and spiraling cephalad. EVL is vastly superior to endoscopic sclerotherapy, with significantly higher initial hemostasis rates, lower rebleeding rates, and fewer complications (e.g., esophageal strictures, deep ulcerations, or mediastinitis).

Gastric Varices : Isolated gastric fundal varices (IGV1) or gastroesophageal varices extending along the fundus (GOV2) are driven by high-flow splenorenal shunts. EVL on large fundal varices carries a high risk of catastrophic tearing and rebleeding upon band sloughing. The preferred endoscopic therapy is endoscopic cyanoacrylate tissue adhesive glue injection (monomer polymerization upon blood contact seals the vascular lumen) or emergent radiological intervention.

Refractory Variceal Hemorrhage: Balloon Tamponade and Preemptive TIPS

Approximately 10 − 15 % 10-15\% 10 − 15% of patients with acute variceal hemorrhage experience failure of medical and endoscopic therapy, manifesting as persistent active bleeding or massive hemodynamic instability.

Balloon Tamponade (Sengstaken-Blakemore and Minnesota Tubes)

Balloon tamponade devices provide mechanical compression against the bleeding varices at the gastroesophageal junction and gastric cardia. Tamponade is strictly an emergency salvage procedure and temporary bridge ( < 24 hours <24\text{ hours} < 24 hours ) to definitive endovascular or surgical shunt therapy. Sengstaken-Blakemore Tube Deployment Protocol:

1. Endotracheal Intubation (Mandatory prior to insertion)
2. Test Balloons Under Water for Leaks
3. Insert Lubricated Tube via Mouth/Nose into Stomach (>50 cm mark)
4. Insufflate Gastric Balloon with 50 mL Air -> Confirm in Stomach via X-Ray
5. Complete Gastric Insufflation to 250-300 mL Air -> Clamp Lumen
6. Apply 0.5 - 1.0 kg Continuous Traction (Taped to Helmet / C-Collar)
7. Bleeding Persists? -> Inflate Esophageal Balloon to 30-45 mmHg via Manometer
8. Maximum Duration: 24 Hours (Deflate Esophageal Balloon 5 min every 6 hours)

Warning

Critical Safety Rules for Balloon Tamponade :

Mandatory Intubation : Never insert a Blakemore or Minnesota tube in an un-intubated patient. Airway compromise, esophageal rupture with displacement into the larynx, and fatal pulmonary aspiration occur frequently if the airway is unprotected.

Air Only for Inflation : Never inflate balloons with water or saline. Liquid increases balloon deadweight, tears the gastric wall, and cannot be rapidly evacuated in an acute emergency.

Radiographic Confirmation : Always verify that the gastric balloon is entirely within the stomach via portable chest/abdominal radiography before fully inflating to 250 − 300 mL 250-300\text{ mL} 250 − 300 mL or applying traction. Accidental inflation of a 300 mL 300\text{ mL} 300 mL balloon inside the mid-esophagus causes fatal full-thickness esophageal rupture.

Time Restrictions : Tamponade pressure causes progressive mucosal ischemia and necrosis. Maintain for a maximum of 24 hours. If an esophageal balloon is inflated, monitor pressure with an aneroid manometer ( 30 − 45 mmHg 30-45\text{ mmHg} 30 − 45 mmHg ) and deflate for 5 minutes every 6 hours to prevent transmural transmucosal gangrene.

Early Preemptive TIPS

The landmark trial by García-Pagán et al. (NEJM 2010) demonstrated that an early preemptive Transjugular Intrahepatic Portosystemic Shunt (TIPS) placed within 24 to 72 hours of admission significantly reduces treatment failure (rebleeding) and 1-year mortality compared to standard medical plus endoscopic therapy in high-risk cirrhotic patients:

High-Risk Criteria :

Child-Pugh class C (score 10 to 13 points); OR

Child-Pugh class B (score ≥ 7 \ge 7 ≥ 7 points) with active bleeding identified at diagnostic endoscopy despite ongoing vasoactive infusion.

TIPS creates an expandable low-resistance polytetrafluoroethylene (PTFE)-covered metallic stent between the high-pressure portal vein and the low-pressure hepatic vein, dramatically decompressing the portal venous system and eliminating the underlying driver of variceal rupture.

Acute Lower Gastrointestinal Bleeding (LGIB) in the ICU

Acute lower gastrointestinal bleeding (LGIB) refers to bleeding originating anatomically distal to the ligament of Treitz, encompassing the small bowel, colon, and anorectum. Severe, hemodynamically significant LGIB in the ICU is predominantly arterial or rapid mucosal capillarovenous hemorrhage.

Primary Etiologies in Critical Care

Diverticular Hemorrhage : The most common cause of massive arterial LGIB ( 30 − 40 % 30-40\% 30 − 40% of cases). Typically presents as acute, painless, large-volume hematochezia. Bleeding results from asymmetric transmural mechanical stress at the fundus of the diverticulum, where penetrating nutrient arterioles (vasa recta) stretch and erode over the dome.

Angiodysplasia (Arteriovenous Malformations) : Dilated, tortuous submucosal venules and capillaries, most commonly found in the cecum and ascending colon of elderly patients ( > 65 >65 > 65 years). Associated with end-stage renal disease and aortic stenosis ( Heyde syndrome , where shear stress through the stenotic aortic valve cleaves high-molecular-weight multimers of von Willebrand factor, inducing acquired Type 2A vWD).

Ischemic Colitis : Driven by transient non-occlusive low-flow states (systemic hypotension, shock, cardiac surgery, high-dose vasopressors). Classically involves "watershed" regions with tenuous collateral networks: Griffiths' point (splenic flexure, between superior and inferior mesenteric arteries) and Sudeck's point (rectosigmoid junction). Patients characteristically present with acute, crampy lower abdominal pain followed within 12 to 24 hours by bloody diarrhea (rarely massive).

Diagnostic and Interventional Algorithm [Acute Massive Lower GI Bleeding in ICU]
│

Hemodynamically Unstable / Exsanguinating?

├── YES ──> Exclude Upper Source (Brisk duodenal ulcer in 10-15%)
│ │ (Urgent NG Lavage or Bedside EGD)
│ ▼
│ Urgent Multiphase Abdominal CTA (No oral contrast)
│ │
│ ├── Extravasation Seen (Rate ≥0.3-0.5 mL/min)
│ │ └── Urgent Catheter Angiography + TAE (Microcoils)
│ └── Negative CTA ──> Resuscitate + Colonoscopy Purge
│
└── NO ──> Hemodynamically Stable / Resuscitated
│
├── Rapid Polyethylene Glycol (PEG) Purge (4-6 L)
└── Early Colonoscopy within 24 Hours

Modality Threshold Bleeding Rate Advantages Critical Limitations / Risks

Multidetector CTA ≥ 0.3 − 0.5 mL/min \ge 0.3 - 0.5\text{ mL/min} ≥ 0.3 − 0.5 mL/min Rapid ( < 10 minutes <10\text{ minutes} < 10 minutes ); non-invasive; 100% anatomical coverage; zero bowel preparation Requires IV iodinated contrast; non-therapeutic (requires subsequent intervention)

Catheter Angiography & TAE ≥ 0.5 − 1.0 mL/min \ge 0.5 - 1.0\text{ mL/min} ≥ 0.5 − 1.0 mL/min Immediate therapeutic superselective microcoil embolization; no bowel prep required Invasive; contrast-induced nephropathy; groin hematoma; bowel infarction risk ( < 3 % <3\% < 3% )

Colonoscopy Any rate Diagnostic and therapeutic (clips, thermal); directly visualizes mucosa Mandates extensive rapid oral purge ( 4 − 6 L 4-6\text{ L} 4 − 6 L ); poor yield and high perforation risk in unprepped bowel

Technetium-99m RBC Scan ≥ 0.05 − 0.1 mL/min \ge 0.05 - 0.1\text{ mL/min} ≥ 0.05 − 0.1 mL/min Highly sensitive for intermittent, low-volume bleeding Extremely poor spatial/anatomical localization; slow acquisition; non-therapeutic